BioSpace News Archive

A fresh business intelligence publication by TMR Research has projected the demand in the global genome editing or engineering market to expand at a notable CAGR during the forecast period of 2017 to 2025.

BioInvent International AB announces that it will host a Key Opinion Leader call on enhancing checkpoint inhibitors for the treatment of solid cancers on Tuesday, July 21, 2020 at 10 a.m. Eastern Time.

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, provided an interim update for the Phase 2 portion of its NC318 monotherapy phase 1/2 trial.

Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, reported preliminary unaudited second quarter 2020 revenue and provided an operational update.

Quest Diagnostics Incorporated, the world’s leading provider of diagnostic information services, announced preliminary financial results for the second quarter ended June 30, 2020.

Pfizer Inc. and BioNTech SE announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program being developed to help protect against SARS-CoV-2, received Fast Track designation from the U.S. Food and Drug Administration.

Lannett Company, Inc. announced a restructuring and cost savings plan.

Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced that it has dosed the first patients in its Phase 1b clinical trial of the arginase inhibitor CB-280 in adult patients with cystic fibrosis and chronic airway infection.

Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, announced that it has completed a successful pre-New Drug Application meeting with the U.S. Food and Drug Administration for AXS-05 for the treatment of major depressive disorder.

Versatile designs, intuitive interfaces and precision systems provide patients with proven respiratory therapies